Benzinga | Nov 23, 2021 07:30AM EST

EXCLUSIVE: Pasithea Therapeutics' Subsidiary Pasithea Clinics Reports It Has Been Approved To Provide Esketamine Nasal Spray (SPRAVATO) For Treatment-Resistant Depression In Adults

Miami Beach, FL / November 23, 2021 -- Pasithea Therapeutics Corp. (Nasdaq:

KTTA) ("Pasithea" or the "Company"), a novel biotechnology company focused

on the research and discovery of new and effective treatments for psychiatric

and neurological disorders, today announced that its wholly owned subsidiary,

Pasithea Clinics, has been approved to provide esketamine nasal spray

(SPRAVATO(r)) for treatment-resistant depression in adults, and has begun

offering the treatment in its Knightsbridge, London location. Only three clinics in

the U.K. have been accredited to offer this treatment.

"This is an important milestone for our U.K. clinics and their patients," stated Dr.

Tiago Reis Marques, CEO of Pasithea Therapeutics. "Major Depression is the

leading cause of long-term disability worldwide. Current treatments have limited

success and up to 30% of patients with depression do not respond to consecutive

trials of antidepressant treatment. These patients are considered to have

treatment-resistant depression and new treatment options are urgently needed."

"Esketamine is safe and effective, especially when combined with ongoing

psychiatric support. Due to some risks associated with this drug, patients treated

in outpatient settings must be enrolled in a specific program. We are extremely

proud to have been accredited to provide this treatment, a reflection of our high

standards of care," said Dr. Yassine Bendiabdallah, Managing Director of

Pasithea Clinics in the U.K.

About SPRAVATO(r)

SPRAVATO(r) (esketamine) CIII nasal spray is a non-selective, non-competitive

antagonist of the N-methyl-D-aspartate (NMDA) receptor -- an ionotropic

glutamate receptor. It has a novel mechanism of action, meaning it works

differently than currently available therapies for major depressive disorder

(MDD).

SPRAVATO(r) is approved in the United States, in conjunction with an oral

antidepressant, to treat adults with treatment-resistant depression (TRD) and

depressive symptoms in adults with MDD with acute suicidal ideation or

behavior. SPRAVATO(r) has been submitted for health authorities' review for TRD

and adults with MDD who have current suicidal ideation with intent in other

markets around the world, including Europe.

About Pasithea Therapeutics Corp.

Pasithea Therapeutics Corporation is a U.S. biotechnology company focused on

the research and discovery of new and effective treatments for psychiatric and

neurological disorders. With an experienced team of experts in the fields of

neuroscience and psychopharmacology, Pasithea is developing new molecular

entities for the treatment of psychiatric and neurological disorders. Pasithea is

also focused on addressing the needs of patients currently suffering with mental

illness by providing access to IV ketamine infusions both in clinics and in-home

settings.

Forward Looking Statements

This press release contains statements that constitute "forward-looking

statements." Forward-looking statements are subject to numerous conditions,

many of which are beyond the control of the Company. While the Company

believes these forward-looking statements are reasonable, undue reliance should

not be placed on any such forward-looking statements, which are based on

information available to the Company on the date of this release. These forward-

looking statements are based upon current estimates and assumptions and are

subject to various risks and uncertainties, including, without limitation, those set

forth in the Company's filings with the SEC. Thus, actual results could be

materially different. The Company undertakes no obligation to update these

statements whether as a result of new information, future events or otherwise,

after the date of this release, except as required by law.